{"schema_version":"secwatch.filing_event.v1","accession":"0000950170-24-059508","form_type":"8-K","ticker":"BCAB","cik":"0001826892","company_name":"BioAtla, Inc.","filed_at":"2024-05-14T23:59:59+00:00","discovered_at":"2026-05-14T18:03:20.452482+00:00","generated_at":"2026-06-02T01:09:58.280014+00:00","sec_items":["2.02","9.01"],"event_type":"earnings","sentiment":"positive","materiality_score":0.7,"calibrated_materiality_score":0.7,"confidence":"high","headline":"BioAtla Q1 net loss $23.2M, cash $80.6M; positive Phase 2 data for ozuriftamab vedotin and evalstotug","bullets":["Net loss $23.2M in Q1 2024 vs $27.5M in Q1 2023; cash $80.6M as of March 31, 2024.","Ozuriftamab vedotin in SCCHN: 11 total responses (5 confirmed incl. 1 CR), 86% DCR; FDA meeting for potential registrational trial expected 2H 2024.","Evalstotug: DLT clearance at 1 gram in 2Q 2024; Phase 2 monotherapy data 2Q 2024; FDA meeting for BRAF-mutated melanoma registrational trial in 2H 2024.","Mecbotamab vedotin in UPS: initial 20 patients enrolled; FDA meeting for remaining trial portion 2H 2024.","CAB-Nectin4-ADC (BA3361) received FDA IND clearance in May 2024."],"urls":{"canonical":"https://secwatch.observer/filing/0000950170-24-059508","json":"https://secwatch.observer/filing/0000950170-24-059508.json","markdown":"https://secwatch.observer/filing/0000950170-24-059508.md","text":"https://secwatch.observer/filing/0000950170-24-059508.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1826892/000095017024059508/0000950170-24-059508-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1826892/000095017024059508/bcab-20240514.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-06-02T01:09:58.280014+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[{"claim_id":"c2a6ddfac4ad7426b4999bb665a5fee33cebbca7","claim":"BioAtla, Inc. reported financial results for the quarter ended March 31, 2024.","evidence_excerpt":"On May 14, 2024, BioAtla, Inc. issued a press release announcing its financial results for the quarter ended March 31, 2024 and provided an update on its ongoing clinical programs.","evidence_source":"SEC 8-K Item 2.02","evidence_url":"https://www.sec.gov/Archives/edgar/data/1826892/000095017024059508/0000950170-24-059508-index.htm","confidence":0.9,"family_label":"Earnings Releases","details":[{"label":"Period","value":"the quarter ended March 31, 2024"},{"label":"Result","value":"reported results"}],"fact_type":"earnings_release"}],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}